INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		09675323		
Filing Date		2000-09-28		
First Named Inventor Henry		Lardy		
Art Unit		1623		
Examiner Name Elli Pe		selev		
Attorney Docket Number		208.3A2		

					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	ber Kind Code ¹ Issue Date Name of Patentee or Applicar of cited Document			t Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1									
If you wisl	h to a	l dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines where ant Passages or Relev s Appear	
	1									
If you wisl	h to a	dd additional U.S. Publ	ished Ap					d button		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patentee Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	тя
	1									С
If you wisl	h to a	l dd additional Foreign F	atent Do	cument	citation	information pl	lease click the Add	button	Add	_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Cite Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Ţ5				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09675323
Filing Date		2000-09-28
First Named Inventor Henry		Lardy
Art Unit		1623
Examiner Name Elli Pe		selev
Attorney Docket Number		208.3A2

	1	JAIN, A., et al., Compass: Predicting biological activities from molecular surface properties. Performance companisons on a steroid benchmark, J. Med. Chem., 1994, pps 2315-27, 37	
	2	LARDY, H., et al., Ergosterods. Il: Biologically active metabolites and synthetic derivatives of dehydroeplandrosterone, Sleroids, 1999, pps. 158-65, 63	
	3	LOUGHNEY, D., et al., A comparison of progestin and androgen receptor binding using the CoMFA technique, J. Computer-Aided Molecular Design, 1992, pps. 569-81, 6	
	4	MARWAH, P., et. al. C19-steroids as androgen receptor modulators: design, discovery, and structure-activity relationship of new steroidal androgen receptor antagonist, Bioorg & Med. Chem., 2006, pps. 5933-47, 14	
	5	WALLER, C, et al., Three-dimensional quantitative structure-activity relationships for androgen receptor ligands, Tox and Applied Pharmacology, 1996, pps. 219-37, 137	
If you wis	h to a	d additional non-patent literature document citation information please click the Add button Add	
		EXAMINER SIGNATURE	
Examiner	r Signa	ure Date Considered	
		ial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a	

F

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04; 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document Surriculture 1.3 - 1 supplies a parameter pattern in the parameter of the Engish language translation is attached

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09675323
Filing Date		2000-09-28
First Named Inventor Henry		Lardy
Art Unit		1623
Examiner Name	Elli Po	iselev
Attorney Docket Number		208.3A2

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFF 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Angelo J. Castellino

□ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

52 707

form of the signature.						
	Signature	/Angelo Castellino/	Date (YYYY-MM-DD)	2007-02-22		

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bs. 1450, Alexandric, V.S. 2311-1450. DIOR SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bs. 1450, Alexandrica, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95-79) requires that you be given centain information in connection with your submission of the stacked form related to a penter application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is SU S. C. (2b)(2); (2) furnishing of the information solicided to is coluntary, and (3) the principal purpose for which the information is used by the U.S. Patent and Trademan XOTIEs is to process and/or examine your submission related to a patent agricultant or patent. If you do not furnish the requested process and/or examine your submission related to a patent agricultant or patent. If you do not furnish the requested requirement of the patent of the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing coursel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the suited matter of the record
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals or part individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S. C. 152(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may fed
 isclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the accord was filed in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application peen to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.